Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T67022
|
||||
Former ID |
TTDR00960
|
||||
Target Name |
Caspase
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Cardiovascular disorder [ICD10: I00-I99] | |||||
BioChemical Class |
Peptidase
|
||||
Target Validation |
T67022
|
||||
EC Number |
EC 3.4.22.-
|
||||
Drugs and Mode of Action | |||||
References | |||||
Ref 527200 | Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol. 2004 Sep;143(1):33-42. | ||||
Ref 528057 | J Med Chem. 2006 Mar 9;49(5):1613-23.Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. | ||||
Ref 530969 | Eur J Med Chem. 2010 Sep;45(9):3858-63. Epub 2010 May 24.Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.